Acorda Therapeutics, Inc.
Case Number:
7:24-bk-22284
Court:
Nature of Suit:
Firms
Companies
Sectors & Industries:
-
June 11, 2024
Acorda Disclosures Lack Info On Releases, Say Creditors
Drugmaker Acorda Therapeutics Inc. faced objections to its disclosure statement from its creditors committee and the U.S. Trustee's Office, which said it failed to provide enough information about releases in the plan.
-
June 07, 2024
Acorda Therapeutics Gets OK On $185M Ch. 11 Sale To Merz
Drugmaker Acorda Therapeutics Inc. received a New York bankruptcy judge's approval Friday to complete a $185 million sale of its assets to a fellow pharmaceutical company, allowing Acorda to move ahead with a Chapter 11 plan to wind down its business.
-
May 03, 2024
Acorda Therapeutics Strikes Creditor Deal On Ch. 11 Loan
A New York judge on Friday gave final approval to Acorda Therapeutics' $60 million Chapter 11 financing package after hearing the drug developer and the lenders had resolved objections lodged by unsecured creditors.
-
April 04, 2024
Acorda Gets Interim OK For $60M DIP With $40M Rollup
Acorda Therapeutics Inc., a developer of drug treatments for neurological disorders, received on Thursday interim approval to access $10 million of a $60 million debtor-in-possession loan package from a group of prepetition noteholders.
-
April 04, 2024
Meet The Attys In Acorda Therapeutics' Ch. 11
Attorneys from Baker McKenzie LLP are representing Acorda Therapeutics in its Chapter 11 bankruptcy in New York as it moves toward a sale of its assets to another pharmaceutical company.
-
April 02, 2024
Acorda Therapeutics Hits Ch. 11, Plans $185M Drug Sale
Neurological disorders drugmaker Acorda Therapeutics Inc. filed for Chapter 11 protection in New York bankruptcy court, with plans to sell its assets to another pharmaceutical company for $185 million.